Teva Pharmaceutical Industries Limited

Day range

$39.15 – $40.12

Open

$39.22

Prev close

$39.41

Volume

6.02M

Market cap

$45.96B

Shares out

1.17B

P/E

65.01

P/S

2.65

P/B

5.93

P/FCF

34.10

ROE

9.1%

ROA

1.8%

Debt/Equity

2.14

Div yield

0.00%

As of Oct 23, 2026

• Guarantee or letter of creditSep 16, 2026

  “The Euro Notes and the USD Notes are senior unsecured obligations of Teva Finance II, Teva Finance III and Teva Finance IV, respectively, and the Notes are guaranteed on a senior unsecured basis by the Company.”

• Listing transferSep 14, 2026

  On September 14, 2026, Teva Pharmaceutical Industries Ltd. (the "Company") began trading its ordinary shares on the New York Stock Exchange, in lieu of its American depositary shares ("ADSs"), under the same ticker symbol under which the ADSs previously traded, "TEVA". The Company's ordinary shares continue to trade on the Tel Aviv Stock Exchange under the same symbol, "TEVA".

• Debt issuanceSep 11, 2026

  On September 9, 2026, Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V. and Teva Pharmaceutical Finance Netherlands IV B.V., with the Company as guarantor, entered into an underwriting agreement providing for the offer and sale of €1,000,000,000 aggregate principal amount of 4.250% Senior Notes due 2033, €500,000,000 aggregate principal amount of 4.625% Senior Notes due 2036, $1,000,000,000 aggregate principal amount of 5.500% Senior Notes due 2034, $1,000,000,000 aggregate principal amount of 5.750% Senior Notes due 2037, and $1,200,000,000 aggregate principal amount of 5.250% Senior Notes due 2032.

• Strategic initiativeSep 3, 2026

  As previously disclosed and as reflected in the Original Report, in alignment with Teva's Pivot to Growth strategy, commencing January 1, 2026, Anda, Teva's distribution business in the U.S., is no longer reported under the Company's United States segment, and, from that date, Anda is reported as part of the Company's Other Activities. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation.

• Annual meeting resultsMay 28, 2026

  Teva Pharmaceutical Industries Limited held its Annual Meeting on May 28, 2026. The shareholders elected to appoint Dr. Sol J. Barer to the Board, to serve until Teva's 2029 annual meeting of shareholders, with 627,816,662 votes for, 245,921,571 against, and 530,682 abstentions.

• ABBVABBVIE INC.+0.39%

Days to cover

5.4

Short interest

29.85M

Avg volume

5.53M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Where Will Neurocrine Biosciences Be in 5 Years?
  positiveThe Motley Fool· Oct 25, 2026
• Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight
  positiveGlobeNewswire Inc.· Oct 19, 2026
• Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGR
  positiveGlobeNewswire Inc.· Oct 16, 2026
• J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down
  neutralZacks Investment Research· Oct 13, 2026
• Teva to Host R&D Day on Wednesday, November 11 in New York City
  positiveGlobeNewswire Inc.· Oct 12, 2026